Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Sernova Biotherapeutics (SEOVF) and Seraxis closed a US$11.2 million financing into Seraxis tied to their proposed merger to form BetaNova Biotherapeutics. The financing comprises convertible notes and common stock purchase warrants; the notes are expected to convert automatically into BetaNova common stock upon merger completion.
The companies expect proceeds to support SR-02 manufacturing, type 1 diabetes patient enrollment in Q4, and first Phase 1/2 dosing in Q1 2027 under an FDA-cleared investigational new drug application. Initial data are anticipated in H1 2027. Plans also target Nasdaq listing readiness in Q1 2027 and advancement of gene-edited SR-03 toward a regulatory submission in H2 2027. The merger remains subject to required approvals and closing conditions. Each company's shareholders are expected to collectively own approximately 50% of BetaNova on a non-diluted basis upon completion.
Sernova Biotherapeutics (SEOVF) and Seraxis will discuss their proposed merger at Noble Capital Markets’ virtual conference on October 1, 2026. Sernova CEO Jonathan Rigby and Seraxis CEO Will Rust will give a joint presentation at 1:30 p.m. Eastern Time, followed by an interactive question-and-answer session.
The companies signed a definitive agreement on September 8, 2026, to combine as BetaNova Biotherapeutics. The discussion will cover Seraxis’ stem cell-derived pancreatic islet programs and manufacturing capabilities alongside Sernova’s implantable Cell Pouch. The merger is expected to close in November 2026, subject to shareholder, court, TSX and other customary approvals and closing conditions.
Sernova Biotherapeutics (SEOVF) investor Dr. Steven Sangha has entered into a voting and support agreement with Seraxis Holdings for Seraxis’s proposed acquisition of all Sernova securities under an arrangement agreement dated September 7, 2026.
Each outstanding Sernova common share is to be exchanged for 0.0112746082 Seraxis common shares, while Sernova shares issued on conversion of subscription receipts from an upcoming private placement are to be exchanged for 0.0132400349 Seraxis common shares, both subject to adjustment. Under the agreement, Dr. Sangha will vote all of his current and future voting Sernova securities in favour of the proposed or any defined alternative transaction and will restrict dispositions of these securities.
He beneficially owns or controls 39,703,667 Sernova shares, 53,575,759 warrants, $2,900,000 of convertible debentures (convertible into 17,909,092 shares), and 2,540,237 options, representing about 10.5% of Sernova’s outstanding shares on a non-diluted basis and about 30.0% on a partially diluted basis.
Sernova Biotherapeutics (SEOVF) will present merger details with Seraxis at the H.C. Wainwright Global Investor Conference on September 16, 2026.
Sernova President and CEO Jonathan Rigby and Seraxis President and CEO Will Rust will deliver a joint in-person presentation at 11:30 a.m. in New York, with a live webcast available to registered attendees via the conference forum. On September 8, 2026, Sernova and Seraxis entered a definitive agreement, subject to shareholder approval, to merge their biotechnologies into BetaNova Biotherapeutics, which is expected to focus on a differentiated type 1 diabetes islet cell replacement approach combining Seraxis’ stem cell-derived islet cells and cGMP platform with Sernova’s Cell Pouch Bio-hybrid Organ.
Sernova (SEOVF) and Seraxis signed a definitive merger agreement to form diabetes-focused BetaNova Biotherapeutics on September 8, 2026.
BetaNova will be a U.S.-domiciled, clinical-stage biotech headquartered in Germantown, Maryland, combining Sernova’s Cell Pouch Bio-hybrid Organ with Seraxis’ stem cell-derived pancreatic islet therapies SR-02 and SR-03 and in-house cGMP manufacturing. On closing, expected in November 2026 subject to shareholder approval, Sernova and Seraxis shareholders will each own about 50% of BetaNova.
A US$10 million non-brokered convertible note financing has been committed by existing insider shareholders, expected to fund SR-02 cGMP production, a Phase 1/2 T1D trial dosing patients in Q1 2027 with data by mid-2027, Nasdaq listing readiness in Q1 2027, and SR-03 IND submission in H2 2027. Notes will convert into non-voting BetaNova stock at merger close.
Sernova Biotherapeutics (OTC:SEOVF) received FDA Orphan Drug Designation for autologous islet transplantation to prevent diabetes following total pancreatectomy. The approach uses Sernova’s Cell Pouch Bio-hybrid Organ to support engraftment and long-term function of a patient’s own insulin-producing islet cells.
The designation, for a rare condition affecting fewer than 200,000 people in the US, provides potential seven years of market exclusivity upon approval, tax credits for qualified clinical testing, and possible FDA user-fee waivers. Sernova is preparing a clinical trial and plans to advance both type 1 and type 3c diabetes programs.
Sernova (OTC:SEOVF) announced final closing of previously disclosed financings after shareholder approval on April 8, 2026. The transactions include a $1.5M unsecured convertible debenture, a $4.0M non-brokered unit financing, and settlements converting $12,700,631 of debt into units.
Certain financings involved insiders and a major vendor and relied on exemptions from formal valuation and minority approval because values did not exceed 25% of market capitalization. Securities issued are subject to statutory hold periods.
Sernova (OTC: SEOVF) reported results from its April 8, 2026 Annual General Meeting. Shareholders voted 93,246,234 common shares (27.31% of outstanding) and reelected all directors.
Resolutions passed include appointing Ernst & Young as auditor; issuing 65,831,880 units to Evotec to settle $12,508,057.25 of debt; issuing units to management to settle $192,574.26; and a private placement of 26,666,667 units to an insider for $4.0 million net proceeds.
Sernova (OTC: SEOVF) closed a non-brokered private placement on March 24, 2026, raising $2.1 million by issuing 13,762,659 units at $0.15 per unit. Each unit includes one common share and one warrant exercisable at $0.25 for 36 months, subject to acceleration.
The financing, together with a $5.5 million commitment from a board member and the expected near-term retirement of approximately $17 million of debt, is intended to strengthen the balance sheet and advance the Cell Pouch Bio-hybrid Organ clinical program for type 1 diabetes.
Sernova (OTC: SEOVF) announced financing transactions totaling $7.1 million on March 4, 2026, including three private financings: $1.6M non‑brokered equity, $1.5M convertible debenture, and $4.0M insider equity subject to shareholder approval.
Proceeds will retire a $4.0M secured term loan if approved and collectively materially improve the company's capital structure and liquidity ahead of an AGM on April 8, 2026.